Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Foghorn Therapeutics (FHTX) EBIT Margin (2020 - 2025)

Foghorn Therapeutics (FHTX) has 5 years of EBIT Margin data on record, last reported at 840.51% in Q4 2024.

  • For Q4 2024, EBIT Margin fell 39922.0% year-over-year to 840.51%; the TTM value through Dec 2024 reached 454.31%, down 13838.0%, while the annual FY2024 figure was 454.31%, 13838.0% down from the prior year.
  • EBIT Margin reached 840.51% in Q4 2024 per FHTX's latest filing, down from 305.48% in the prior quarter.
  • Across five years, EBIT Margin topped out at 97.73% in Q3 2023 and bottomed at 64051.22% in Q3 2021.
  • Average EBIT Margin over 5 years is 6077.74%, with a median of 679.68% recorded in 2022.
  • Peak YoY movement for EBIT Margin: crashed -5372217bps in 2021, then skyrocketed 6362525bps in 2022.
  • A 5-year view of EBIT Margin shows it stood at 8278.49% in 2020, then skyrocketed by 52bps to 3938.57% in 2021, then surged by 81bps to 762.09% in 2022, then surged by 42bps to 441.29% in 2023, then plummeted by -90bps to 840.51% in 2024.
  • Per Business Quant database, its latest 3 readings for EBIT Margin were 840.51% in Q4 2024, 305.48% in Q3 2024, and 386.64% in Q2 2024.